152 related articles for article (PubMed ID: 37028260)
21. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
22. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
24. Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Kam CW; Ruiz FE
Pediatr Pulmonol; 2021 Mar; 56(3):593-613. PubMed ID: 33002306
[TBL] [Abstract][Full Text] [Related]
25. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
[TBL] [Abstract][Full Text] [Related]
26. A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Hansen SA; Aas E; Solli O
Eur J Health Econ; 2020 Feb; 21(1):73-84. PubMed ID: 31512069
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.
Lilyasari O; Subekti Y; Atika N; Dinarti LK; Putri S; Opitasari C; Anggraini AB; Bussabawalai T; Teerawattananon Y
BMC Health Serv Res; 2019 Aug; 19(1):573. PubMed ID: 31412857
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.
Dong W; Zhang Z; Chu M; Gu P; Hu M; Liu L; Huang J; Zhang R
Front Pharmacol; 2023; 14():1122866. PubMed ID: 37637431
[No Abstract] [Full Text] [Related]
29. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Tran-Duy A; Morrisroe K; Clarke P; Stevens W; Proudman S; Sahhar J; Nikpour M;
J Am Heart Assoc; 2021 Apr; 10(7):e015816. PubMed ID: 33759539
[TBL] [Abstract][Full Text] [Related]
30. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
[TBL] [Abstract][Full Text] [Related]
31. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
32. PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.
Weatherald J; Humbert M
Respirology; 2023 Mar; 28(3):212-214. PubMed ID: 36318987
[No Abstract] [Full Text] [Related]
33. Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance.
Yamazaki H; Kobayashi N; Taketsuna M; Tajima K; Suzuki N; Murakami M
Curr Med Res Opin; 2017 Dec; 33(12):2241-2249. PubMed ID: 28699846
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil for Pulmonary Arterial Hypertension.
Bhogal S; Khraisha O; Al Madani M; Treece J; Baumrucker SJ; Paul TK
Am J Ther; 2019; 26(4):e520-e526. PubMed ID: 30946047
[TBL] [Abstract][Full Text] [Related]
35. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
Wung D
Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
[TBL] [Abstract][Full Text] [Related]
36. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
[TBL] [Abstract][Full Text] [Related]
38. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
Li HJ; Bai WJ; Dai YT; Xu WP; Wang CN; Li HZ
Asian J Androl; 2016; 18(5):773-9. PubMed ID: 26459780
[TBL] [Abstract][Full Text] [Related]
39. Cost-Utility of Sildenafil for Persistent Pulmonary Hypertension of the Newborn.
Evers PD; Critser PJ; Cash M; Magness M; Hoelle S; Hirsch R
Am J Perinatol; 2021 Dec; 38(14):1505-1512. PubMed ID: 32615617
[TBL] [Abstract][Full Text] [Related]
40. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
